KR20220106982A - 레트 증후군의 치료 방법 및 조성물 - Google Patents

레트 증후군의 치료 방법 및 조성물 Download PDF

Info

Publication number
KR20220106982A
KR20220106982A KR1020227018117A KR20227018117A KR20220106982A KR 20220106982 A KR20220106982 A KR 20220106982A KR 1020227018117 A KR1020227018117 A KR 1020227018117A KR 20227018117 A KR20227018117 A KR 20227018117A KR 20220106982 A KR20220106982 A KR 20220106982A
Authority
KR
South Korea
Prior art keywords
subject
tropinetide
administered
syndrome
rett
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227018117A
Other languages
English (en)
Korean (ko)
Inventor
모나 다위시
제임스 엠. 유아킴
로렌스 어윈 글래스
낸시 엘리자베스 존스
션 폴 오스터홀트
오스카 델라 파스쿠아
Original Assignee
아카디아 파마슈티칼스 인코포레이티드
뉴렌 파마슈티컬즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아카디아 파마슈티칼스 인코포레이티드, 뉴렌 파마슈티컬즈 리미티드 filed Critical 아카디아 파마슈티칼스 인코포레이티드
Publication of KR20220106982A publication Critical patent/KR20220106982A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Peptides Or Proteins (AREA)
KR1020227018117A 2019-10-28 2020-10-28 레트 증후군의 치료 방법 및 조성물 Pending KR20220106982A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962927008P 2019-10-28 2019-10-28
US62/927,008 2019-10-28
US202063031201P 2020-05-28 2020-05-28
US63/031,201 2020-05-28
PCT/US2020/057627 WO2021086892A1 (en) 2019-10-28 2020-10-28 Methods and compositions for treatment of rett syndrome

Publications (1)

Publication Number Publication Date
KR20220106982A true KR20220106982A (ko) 2022-08-01

Family

ID=75715568

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227018117A Pending KR20220106982A (ko) 2019-10-28 2020-10-28 레트 증후군의 치료 방법 및 조성물

Country Status (14)

Country Link
US (1) US20220339138A1 (https=)
EP (1) EP4051308A4 (https=)
JP (2) JP2022553888A (https=)
KR (1) KR20220106982A (https=)
CN (1) CN115335071A (https=)
AU (1) AU2020376801A1 (https=)
BR (1) BR112022008095A2 (https=)
CA (1) CA3156680A1 (https=)
CL (1) CL2022001079A1 (https=)
CO (1) CO2022007501A2 (https=)
IL (1) IL292617B2 (https=)
MX (1) MX2022004785A (https=)
TW (1) TW202116300A (https=)
WO (1) WO2021086892A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL310045A (en) 2021-07-12 2024-03-01 Acadia Pharm Inc Crystalline forms of tropintide
WO2023242844A1 (en) * 2022-06-15 2023-12-21 Ramot At Tel-Aviv University Ltd. Method and therapeutic agent for treatment of disease or disorder associated with impaired firing rate and/or mitochondrial calcium homeostasis
WO2025262646A1 (en) * 2024-06-22 2025-12-26 Biophore India Pharmaceuticals Pvt. Ltd Dosage forms of trofinetide and its pharmaceutically acceptable salt thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6709817B1 (en) * 1999-09-07 2004-03-23 Baylor College Of Medicine Method of screening Rett syndrome by detecting a mutation in MECP2
US9708366B2 (en) * 2011-01-27 2017-07-18 Neuren Pharmaceuticals Ltd. Treatment of fragile X syndrome using glycyl-L-2-methylprolyl-L-glutamate
WO2014130691A2 (en) * 2013-02-20 2014-08-28 Theravasc Inc. Pharmaceutical formulations of nitrite and uses thereof
WO2015013397A2 (en) * 2013-07-25 2015-01-29 Neuren Pharmaceuticals Limited Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders
US20150224164A1 (en) * 2013-11-26 2015-08-13 Neuren Pharmaceuticals Limited Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid
GB2554064B (en) * 2016-09-01 2019-11-20 Jit Singh Shailinder An enteral feeding tube

Non-Patent Citations (66)

* Cited by examiner, † Cited by third party
Title
Amir RE, Van den Veyver IB, Schultz R, et al. Influence of mutation type and X chromosome inactivation on Rett syndrome phenotypes. Ann Neurol. 2000;47:670-679.
Anagnostou E, Jones N, Huerta M, et al. Measuring Social Communication Behaviors as a Treatment Endpoint in Individuals with Autism Spectrum Disorder. Autism. 2015;19(5):622-36.
Barnes KV, Coughlin FR, O'Leary HM, et al. Anxiety-like behaviour in Rett syndrome: characteristics and assessment by anxiety scales. J Neurodev Disord. 2015:7(1):30.
Bienvenu T, Philippe C, De Roux N, et al. The incidence of Rett syndrome in France. Pediatr Neurol. 2006;34(5):372-375.
Buchovecky CM, Turley SD, Brown HM, et al. A suppressor screen in Mecp2 mutant mice implicates cholesterol metabolism in Rett syndrome. Nat Genet. 2013;45(9):1013-1020.
Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry. 2007;Jul;4(7):28-37.
Byiers BJ, Symons FJ. Issues in estimating developmental level and cognitive function in Rett syndrome. In: Hodapp RM ed. International Review of Research in Intellectual and Developmental Disabilities. Waltham, MA: Elsevier Inc.; 2012;43:147-185.
Camfield C, Breau L, Camfield P. Assessing the impact of pediatric epilepsy and concomitant behavioral, cognitive, and physical/neurologic disability: Impact of Childhood Neurologic Disability Scale. Dev Med Child Neurol. 2003;45:152-159.
Cass H, Reilly S, Owen L, et al. Findings from a multidisciplinary clinical case series of females with Rett syndrome. Dev Med Child Neurol. 2003;45:325-337.
Cianfaglione R, Clarke A, Kerr M, et al. A national survey of Rett syndrome: behavioural characteristics. J Neurodev Disord. 2015;7(1):11.
Cianfaglione R, Clarke A, Kerr M, Hastings RP, Oliver C, Felce D. Ageing in Rett syndrome. J Intellect Disabil Res. 2016;60(2):182-190.
Clarkson T, LeBlanc J, DeGregorio G, et al. Adapting the Mullen Scales of Early Learning for a standardized measure of cognition in children with Rett syndrome. Intellect Dev Disabil. 2017;55(6):419-431.
Djukic A, McDermott MV. Social preferences in Rett syndrome. Pediatr Neurol. 2012;46(4):240-242.
Downs J, Bebbington A, Jacoby P, et al. Level of purposeful hand function as a marker of clinical severity in Rett syndrome. Dev Med Child Neurol. 2010;52(9):817-823.
Downs J, Bebbington A, Kaufmann WE, Leonard H. Longitudinal hand function in Rett syndrome. J Child Neurol. 2011;26(3):334-340.
Ehrhart F, Coort SL, Cirillo E, Smeets E, Evelo CT, Curfs L. New insights in Rett syndrome using pathway analysis for transcriptomics data. Wien Med Wochenschr. 2016;166:346-352.
Epstein A, Leonard H, Davis E, et al. Conceptualizing a quality of life framework for girls with Rett syndrome using qualitative methods. Am J Med Genet A. 2016;170(3):645-653.
Glaze DG, Neul JL, Kaufmann WE, et al. Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome. Neurology. 2019 Mar 27. pii: 10.1212/WNL.0000000000007316. [Epub ahead of print].
Glaze DG, Neul JL, Percy A, et al. A double-blind, randomized, placebo-controlled clinical study of trofinetide in the treatment of Rett syndrome. Pediatr Neurol. 2017;76:37-46.
Glaze DG, Percy AK, Skinner S, et al. Epilepsy and the natural history of Rett syndrome. Neurology. 2010;74:909-912.
Hite KC, Adams VH, Hansen JC. Recent advances in MeCP2 structure and function. Biochem Cell Biol. 2009;87(1):219-227.
ICH Harmonized Tripartite Guideline: Clinical Safety Data Management: Definitions and Standards for Expedited Reporting E2A. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. October 1994.
Iemmi V, Knapp M, Brown FJ. Positive behavioural support for children and adolescents with intellectual disabilities whose behaviour challenges: an exploration of the economic case. J Intellect Disabil. 2015;20(3):281-295.
Ip JPK, Mellios N, Sur M. Rett syndrome: insights into genetic, molecular and circuit mechanisms. Nat Rev Neurosci. 2018;19(6):368-382.
Jusko WJ, Chiang ST. Distribution volume related to body weight and protein binding. J Pharm Sci. 1982;71(4):469-70.
Kaufmann WE, Tierney E, Rohde CA, et al. Social impairments in Rett syndrome: characteristics and relationship to clinical severity. J Intellect Disabil Res. 2012;56(3):233-247.
Kerr AM, Armstrong DD, Prescott RJ, Doyle D, Kearney DL. Rett syndrome: analysis of deaths in the British survey. Eur Child Adolesc Psychiatry. 1997;6 Suppl 1:71-74.
Kersting G, Willmann S, Wurthwein G, et al. Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children. Cancer Chemother Pharmacol. 2012 Feb;69(2):397-405.
Khwaja O, Ho E, Barnes KV, et al. Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. Proc Natl Acad Sci U.S.A. 2014;111(12):4596-4601.
Kriaucionis S, Bird A. DNA methylation and Rett syndrome. Hum Mol Genet. 2003;12 Spec No 2:R221-227.
Krishnaraj R, Ho G, Christodoulou J. RettBASE: Rett syndrome database update. Hum Mutat. 2017;38(8):922-931.
Lane J, Salter A, Jones NE, et al. Assessment of Caregiver Inventory for Rett syndrome. J Autism Dev Disord. 2017;47(4). 1102-1112.
Larsson G, Lindstrφm B, Witt Engerstrφm I. Rett syndrome from a family perspective: the Swedish Rett Center Survey. Brain Dev. 2005;27 Suppl 1:S14-19.
Lee JY, Leonard H, Piek JP, Downs J. Early development and regression in Rett syndrome. Clin Genet. 2013;84(6):572-576.
Monros E, Armstrong J, Aibar E, Poo P, Canos I, Pineda M. Rett syndrome in Spain: mutation analysis and clinical correlations. Brain & Development. 2001;23:S251-S253.
Motil KJ, Caeg E, Barrish JO, et al. Gastrointestinal and nutritional problems occur frequently throughout life in girls and women with Rett syndrome. J Pediatr Gastroenterol Nutr. 2012;55(3):292-298.
Mount RH, Charman T, Hastings RP, Reilly S, Cass H. Features of autism in Rett syndrome and severe mental retardation. J Autism Dev Disord. 2003;33(4):435-442.
Mount RH, Charman T, Hastings RP, Reilly S, Cass H. The Rett Syndrome Behaviour Questionnaire (RSBQ): Refining the behavioural phenotype of Rett syndrome. J Child Psychol Psychiatry. 2002;43(8):1099-1110.
Mount RH, Hastings RP, Reilly S, Cass H, Charman T. Behavioural and emotional features in Rett syndrome. Disabil Rehabil. 2001;23(3-4):129-138.
Neul JL, Benke TA, Marsh ED, et al. The array of clinical phenotypes of males with mutations in Methyl-CpG binding protein 2. Am J Med Genet B Neuropsychiatr Genet. 2019;180(1):55-67.
Neul JL, Fang P, Barrish J, et al. Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome. Neurology. 2008;70(16):1313-1321.
Neul JL, Glaze D, Percy A, et al. Improving Treatment Trial Outcomes for Rett Syndrome: the development of Rett-specific anchors for the Clinical Global Impression Scale. J Child Neurol. 2015;30(13):1743-1748.
Neul JL, Kaufmann WE, Glaze DG, et al. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol. 2010;68(6):944-950.
Neul JL, Lane JB, Lee HS, et al. Developmental delay in Rett syndrome: data from the natural history study. J Neurodevelop Dis. 2014;(30):2-9.
Novak M, Guest C. Application of a multidimensional Caregiver Burden Inventory. Gerontologist. 1989;29(6):798-803.
O'Leary HM, Kaufmann WE, Barnes KV, et al. Placebo controlled crossover efficacy assessment of mecasermin for the treatment of Rett syndrome. Ann Clin Transl Neurol 2018;5(3):323-332.
Oosterholt SP, Horrigan J, Jones N, Glass L, Della Pasqua O. Population pharmacokinetics of NNZ-2566 in healthy subjects. Eur J Pharm Sci. 2017;15;109S:S98-107.
Palacios-Cena D, Famoso-Perez P, Salom-Moreno J, et al. "Living an Obstacle Course": A Qualitative Study Examining the Experiences of Caregivers of Children with Rett Syndrome. Int. J Environ Res Public Health. 2018;16(1):41.
Percy AK, Lane J, Annese F, Warren H, Skinner SA, Neul JL. When Rett syndrome is due to genes other than MECP2. Transl Sci Rare Dis. 2018;3(1):49-53.
Percy AK, Lee HS, Neul JL, et al. Profiling scoliosis in Rett syndrome. Pediatr Res. 2010;67(4):435-439.
Perry A, Sarlo-McGarvey, Haddad, C. Brief report: cognitive and adaptive functioning in 28 girls with Rett syndrome. J Autism Dev Disord. 1991;21(4):551-556.
Piana C, Zhao W, Adkison K, et al. Covariate effects and population pharmacokinetics of lamivudine in HIV-infected children. Br J Clin Pharmacol. 2014;77(5):861-72.
Robertson L, Hall SE, Jacoby P, Ellaway C, de Klerk N, Leonard H. The association between behaviour and genotype in Rett syndrome using the Australian Rett syndrome database. Am J Med Genet. 2006;141B(2):177-183.
Rose SA, Djukic A, Jankowski JJ, Feldman JF, Fishman I, Valicenti-McDemott M. Rett syndrome: an eye-tracking study of attention and recognition memory. Dev Med Child Neurol. 2013;55(4):364-371.
Samaco RC, Neul JL. Complexities of Rett syndrome and MeCP2. J Neurosci. 2011;31(22):7951-7959.
Shovlin S, Tropea D. Transcriptome level analysis in Rett syndrome using human samples from different tissues. Orphanet J Rare Dis. 2018;13(1):113.
Thompson RH, Iwata BA. A descriptive analysis of social consequences following problem behavior. J Appl Behav. Anal. 2001;34(2):169-178.
Tropea D, Giacomettim E, Wilson NR, et al. Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. PNAS. 2009;106:2029-2034.
Urbanowicz A, Downs J, Girdler SJ, Ciccone NA, Leonard H. An exploration of the use of eye gaze and gestures in females with Rett syndrome. J Speech Lang Hear Res. 2016;59(6):1373-1383.
Urbanowicz A, Downs J, Girdler SJ, Ciccone NA, Leonard H. Aspects of speech language abilities are influenced by MECP2 mutation type in girls with Rett syndrome. Am J Med Genet. 2015;167A(2):354-362.
West PR, Amaral DG, Bais P, et al. Metabolomics as a tool for discovery of biomarkers of autism spectrum disorder in the blood plasma of children. PLoS One. 2014;9(11):e112445.
Wetherby AM, Allen L, Cleary J, Kublin K, Goldstein H. Validity and reliability of the communication and symbolic behavior scales developmental profile with very young children. J Speech Lang Hear Res. 2002;45(6):1202-1218.
Wetherby AM, Guthrie W, Woods J, et al. Parent-implemented social intervention for toddlers with autism: an RCT. Pediatrics. 2014;134(6):1084-1093.
Woodyatt GC, Ozanne AE. A longitudinal study of cognitive skills and communication behaviours in children with Rett syndrome. J Intellect Disabil Res. 1993;37(Pt 4):419-435.
Yasui DH, Xu H, Dunaway KW, Lasalle JM, Jin LW, Maezawa I. MeCP2 modulates gene expression pathways in astrocytes. Mol Autism. 2013;4(1):3.
Young DJ, Bebbington A, Anderson A, et al. The diagnosis of autism in a female: could it be Rett syndrome? Eur J Pediatr. 2008;167(6):661-669.

Also Published As

Publication number Publication date
CN115335071A (zh) 2022-11-11
TW202116300A (zh) 2021-05-01
CA3156680A1 (en) 2021-05-06
CL2022001079A1 (es) 2023-04-21
EP4051308A4 (en) 2023-08-23
MX2022004785A (es) 2022-05-16
CO2022007501A2 (es) 2022-08-30
US20220339138A1 (en) 2022-10-27
AU2020376801A1 (en) 2022-06-09
IL292617B1 (en) 2025-11-01
IL292617B2 (en) 2026-03-01
EP4051308A1 (en) 2022-09-07
WO2021086892A1 (en) 2021-05-06
BR112022008095A2 (pt) 2022-07-12
IL292617A (en) 2022-07-01
JP2025148461A (ja) 2025-10-07
JP2022553888A (ja) 2022-12-26

Similar Documents

Publication Publication Date Title
US20250154234A1 (en) Methods for treatment of refractory generalized myasthenia gravis
US20220339138A1 (en) Methods and compositions for treatment of rett syndrome
JP2025036702A (ja) 神経認知障害、慢性疼痛を治療し、炎症を低減させる方法
US12138254B2 (en) Chronic nightly dosing of lasmiditan for migraine prevention
Toledo et al. Long-term safety, efficacy, and quality of life during adjunctive brivaracetam treatment in patients with uncontrolled epilepsy: an open-label follow-up trial
KR20210149028A (ko) 우울증의 치료 방법
Ben-Menachem et al. Safety, tolerability, and efficacy of brivaracetam as adjunctive therapy in patients with focal seizures, generalized onset seizures, or Unverricht–Lundborg disease: an open-label, long-term follow-up trial
Egeberg et al. Clinical overview of dalfampridine: an agent with a novel mechanism of action to help with gait disturbances
Evans et al. Efficacy and safety of the melanocortin pan-agonist PL9643 in a phase 2 study of patients with dry eye disease
Wirta et al. Phase 2b, randomized, 3-month, dose-finding study of sepetaprost in patients with primary open-angle glaucoma or ocular hypertension: the ANGEL study
US10195165B2 (en) Methods of treating Prader-Willi syndrome
de Leon-Casasola New developments in the treatment algorithm for peripheral neuropathic pain
Williams et al. Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis
EA051935B1 (ru) Способы и композиции для лечения синдрома ретта
Sadikova et al. The effect of melatonin supplement use on pubertal timing: target trial emulation in the Adolescent Brain Cognitive Development study
CA3111205C (en) Chronic nightly dosing of lasmiditan for migraine prevention
Handa et al. PSYCHIATRIC EMERGENCIES
Sada et al. FRI0218 PREVALENCE, BURDEN OF DISEASE AND HEALTHCARE UTILIZATION AMONG PATIENTS WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) IN JAPAN 2005-2017
EP4547256A1 (en) Methods for ameliorating cognitive impairment using bile acid derivatives
TW201106944A (en) Exo-S-mecamylamine method, use, and compound for treatment
Data et al. IHC Posters–Saturday and Sunday
BA A randomized, placebo-controlled crossover trial of phentermine-topiramate ER in patients with binge-eating disorder and bulimia nervosa

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902